- Home »
- Market Insights »
- Upcoming Biotech Phase 3 Trial Readouts (June 2026)
Upcoming Biotech Phase 3 Trial Readouts (June 2026)
A calendar of upcoming biotech Phase 3 trial readouts tracked by MarketsHost from public regulatory and clinical-trial sources. Informational only.
by Mubarak
Published Jun 14, 2026 | Updated Jun 14, 2026 | 📖 3 min read
Article continues below advertisement
This calendar tracks upcoming Phase 3 clinical trial readouts for biotechnology companies, organized by expected announcement date. Each entry pairs a company and ticker symbol with a specific drug candidate or development program. Dates are sourced from public regulatory filings and clinical trial registries, though timelines may shift as development progresses.
Phase 3 trial outcomes represent critical inflection points for biotech firms and investors alike. These readouts influence market perception, inform regulatory pathways, and chart the course of clinical development. For those following the sector, monitoring these milestones offers crucial visibility into the pipeline progress of major biotech players and signals within the broader innovation space.
Upcoming Biotech Phase 3 Readouts
| # | Date | Company | Ticker | Drug / Trial |
|---|---|---|---|---|
| 1 | Jun 22, 2026 | HST Global, Inc. | HSTC | A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlima… |
| 2 | Jun 26, 2026 | Option Therapeutics Inc. | OPTN | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequ… |
| 3 | Jun 29, 2026 | NOVO NORDISK A S | NVO | A Research Study to See if Two Different Formulations of Oral Semaglutide Are… |
| 4 | Jun 30, 2026 | Olema Pharmaceuticals, Inc. | OLMA | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Ad… |
| 5 | Jun 30, 2026 | ADC Therapeutics SA | ADCT | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated … |
| 6 | Jun 30, 2026 | BEACON TOPCO, INC. | CLYD | A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal In… |
| 7 | Jun 30, 2026 | Glucose Health, Inc. | GLUC | Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in … |
| 8 | Jun 30, 2026 | NEUTRA CORP. | NTRR | Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on … |
| 9 | Jun 30, 2026 | ELITE PHARMACEUTICALS INC /NV/ | ELTP | Continuation Protocol for Obstructive Sleep Apnea (OSA) |
| 10 | Jun 30, 2026 | Inhibitor Therapeutics, Inc. | INTI | A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Bre… |
| 11 | Jun 30, 2026 | Turn Therapeutics Inc. | TTRX | Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntingt… |
| 12 | Jul 1, 2026 | Pharvaris N.V. | PHVS | Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor |
| 13 | Jul 1, 2026 | Harmony Biosciences Holdings, Inc. | HRMY | A Study of Pitolisant in Patients With Prader-Willi Syndrome |
| 14 | Jul 1, 2026 | Alto Neuroscience, Inc. | ANRO | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadaci… |
| 15 | Jul 1, 2026 | OS Therapies Inc | OSTX | Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients Wit… |
| 16 | Jul 1, 2026 | SOLIGENIX, INC. | SNGX | Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL |
| 17 | Jul 1, 2026 | Ultragenyx Pharmaceutical Inc. | RARE | Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angel… |
| 18 | Jul 1, 2026 | Serina Therapeutics, Inc. | SER | Randomization to Extend Stroke Intravenous ThromboLysis In Evolving Non-Large… |
| 19 | Jul 6, 2026 | OS Therapies Inc | OSTX | Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Tras… |
| 20 | Jul 13, 2026 | Option Therapeutics Inc. | OPTN | A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children an… |
How this list is compiled
Events are sourced from public US-government and clinical-trial data (SEC filings, the Federal Register and ClinicalTrials.gov) and ordered by date. Dates can change; always confirm with primary sources. Figures are pulled automatically from MarketsHost data and refreshed regularly. This page is for general information only and is not investment, financial or trading advice.
For the underlying data, explore the BioPharma FDA catalyst tracker on MarketsHost.
Related Articles
Frequently Asked Questions
. What is a Phase 3 readout?
A Phase 3 readout is the release of results from a large, late-stage clinical trial — a key milestone in a drug's path to potential approval.
. Are these dates guaranteed?
No. Regulatory and trial timelines can move. The calendar reflects the most recent public estimates and should be confirmed against primary sources.
Disclaimer : The above information is for general informational purposes only. All information on the Site is provided in good faith, however we make no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability or completeness of any information on the Site.